DEPOCYT Drug Patent Profile
✉ Email this page to a colleague
When do Depocyt patents expire, and when can generic versions of Depocyt launch?
Depocyt is a drug marketed by Pacira Pharms Inc and is included in one NDA.
The generic ingredient in DEPOCYT is cytarabine. There are fifteen drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the cytarabine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Depocyt
A generic version of DEPOCYT was approved as cytarabine by HIKMA on August 2nd, 1989.
Summary for DEPOCYT
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 123 |
Clinical Trials: | 79 |
Patent Applications: | 4,529 |
Formulation / Manufacturing: | see details |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for DEPOCYT |
DailyMed Link: | DEPOCYT at DailyMed |
Recent Clinical Trials for DEPOCYT
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Kartos Therapeutics, Inc. | Phase 1/Phase 2 |
University of Florida | Phase 2 |
Medical College of Wisconsin | Phase 1 |
Anatomical Therapeutic Chemical (ATC) Classes for DEPOCYT
US Patents and Regulatory Information for DEPOCYT
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pacira Pharms Inc | DEPOCYT | cytarabine | INJECTABLE, LIPOSOMAL;INJECTION | 021041-001 | Apr 1, 1999 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for DEPOCYT
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Pacira Pharms Inc | DEPOCYT | cytarabine | INJECTABLE, LIPOSOMAL;INJECTION | 021041-001 | Apr 1, 1999 | ⤷ Try a Trial | ⤷ Try a Trial |
Pacira Pharms Inc | DEPOCYT | cytarabine | INJECTABLE, LIPOSOMAL;INJECTION | 021041-001 | Apr 1, 1999 | ⤷ Try a Trial | ⤷ Try a Trial |
Pacira Pharms Inc | DEPOCYT | cytarabine | INJECTABLE, LIPOSOMAL;INJECTION | 021041-001 | Apr 1, 1999 | ⤷ Try a Trial | ⤷ Try a Trial |
Pacira Pharms Inc | DEPOCYT | cytarabine | INJECTABLE, LIPOSOMAL;INJECTION | 021041-001 | Apr 1, 1999 | ⤷ Try a Trial | ⤷ Try a Trial |
Pacira Pharms Inc | DEPOCYT | cytarabine | INJECTABLE, LIPOSOMAL;INJECTION | 021041-001 | Apr 1, 1999 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for DEPOCYT
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Pacira Limited | DepoCyte | cytarabine | EMEA/H/C/000317 Intrathecal treatment of lymphomatous meningitis. In the majority of patients such treatment will be part of symptomatic palliation of the disease. |
Withdrawn | no | no | no | 2001-07-11 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for DEPOCYT
See the table below for patents covering DEPOCYT around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Norway | 329401 | ⤷ Try a Trial | |
European Patent Office | 1670433 | FORMULATION PHARMACEUTIQUE TRANSDERMIQUE VISANT A REDUIRE LES RESIDUS SUR LA PEAU (TRANSDERMAL PHARMACEUTICAL FORMULATION FOR MINIMIZING SKIN RESIDUES) | ⤷ Try a Trial |
Japan | 5619337 | ⤷ Try a Trial | |
Australia | 2004220498 | ⤷ Try a Trial | |
Brazil | PI0408153 | ⤷ Try a Trial | |
Japan | 2011236250 | USE AND FORMULATION FOR TRANSDERMAL OR TRANSMUCOSAL APPLICATION OF ACTIVE AGENT | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for DEPOCYT
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1744764 | SPC/GB18/045 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: COMBINATION OF DAUNORUBICIN AND CYTARABINE; REGISTERED: UK EU/1/18/1308/001-003 20180827; UK PLGB 31626/0004 20180827 |
2768484 | LUC00135 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: COMBINATION OF DAUNORUBICIN AND CYTARABINE; AUTHORISATION NUMBER AND DATE: EU/1/18/1308 20180827 |
3300601 | 301185 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: COMBINATIE VAN DAUNORUBICINE EN CYTARABINE; REGISTRATION NO/DATE: EU/1/18/1308 20180827 |
1744764 | 300960 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: COMBINATIE VAN DAUNORUBICINE EN CYTARABINE; REGISTRATION NO/DATE: EU/1/18/1308 20180827 |
3300601 | 2022027 | Norway | ⤷ Try a Trial | PRODUCT NAME: COMBINATION OF DAUNORUBICIN AND CYTARABINE; REG. NO/DATE: EU/1/18/1308 20180831 |
2768484 | 301016 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: COMBINATIE VAN DAUNORUBICINE EN CYTARABINE; REGISTRATION NO/DATE: EU/1/18/1308 20180827 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |